ARWR vs. HCM, ACAD, IDYA, MLTX, FOLD, XENE, MOR, INDV, BHC, and JANX
Should you be buying Arrowhead Pharmaceuticals stock or one of its competitors? The main competitors of Arrowhead Pharmaceuticals include HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), IDEAYA Biosciences (IDYA), MoonLake Immunotherapeutics (MLTX), Amicus Therapeutics (FOLD), Xenon Pharmaceuticals (XENE), MorphoSys (MOR), Indivior (INDV), Bausch Health Companies (BHC), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical preparations" industry.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and HUTCHMED (NASDAQ:HCM) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, community ranking, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.
62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Arrowhead Pharmaceuticals has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500.
In the previous week, Arrowhead Pharmaceuticals and Arrowhead Pharmaceuticals both had 2 articles in the media. HUTCHMED's average media sentiment score of 0.91 beat Arrowhead Pharmaceuticals' score of 0.44 indicating that HUTCHMED is being referred to more favorably in the news media.
Arrowhead Pharmaceuticals presently has a consensus target price of $53.45, suggesting a potential upside of 136.42%. HUTCHMED has a consensus target price of $29.70, suggesting a potential upside of 81.54%. Given Arrowhead Pharmaceuticals' higher possible upside, research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than HUTCHMED.
HUTCHMED has higher revenue and earnings than Arrowhead Pharmaceuticals.
HUTCHMED has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -163.32%. HUTCHMED's return on equity of 0.00% beat Arrowhead Pharmaceuticals' return on equity.
Arrowhead Pharmaceuticals received 209 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 66.74% of users gave HUTCHMED an outperform vote while only 65.25% of users gave Arrowhead Pharmaceuticals an outperform vote.
Summary
HUTCHMED beats Arrowhead Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get Arrowhead Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ARWR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Arrowhead Pharmaceuticals Competitors List
Related Companies and Tools
